Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.83 |
| ▸ | SHBG | P04278 | 6/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.83 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.83 |
| ▸ | BLM | P54132 | 4/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.83 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.83 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.78 |
| ▸ | TSHR | P16473 | 3/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362526 | 1.00 | LMNA (0.83) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| SCHEMBL11264395 | 0.92 | LMNA (0.81) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| SCHEMBL11264397 | 0.92 | LMNA (0.81) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| Hydroxyprogesterone SCHEMBL13558389 | 0.91 | LMNA (1.00) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| Hydroxyprogesterone SCHEMBL18261234 | 0.91 | LMNA (1.00) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| Hydroxyprogesterone SCHEMBL24287585 | 0.91 | LMNA (1.00) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| Hydroxyprogesterone SCHEMBL14546356 | 0.91 | LMNA (1.00) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| Hydroxyprogesterone SCHEMBL14523053 | 0.91 | LMNA (1.00) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| Hydroxyprogesterone SCHEMBL23456341 | 0.91 | LMNA (1.00) | LMNASHBGSMN1; SMN2SERPINA6BLM | |
| Hydroxyprogesterone SCHEMBL265609 | 0.91 | LMNA (1.00) | LMNASHBGSMN1; SMN2SERPINA6BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0238545-B1 | C20 THROUGH C26 AMINO STEROIDS | UPJOHN CO (US) | 1995-11-15 | — | — | EP | claimed |
| EP-0263213-B1 | C20 Through C26 amino steroids | UPJOHN CO (US) | 1995-09-06 | — | — | EP | claimed |
| WO-2013133980-A1 | NITROXY DERIVATIVES OF SOFT STEROIDS | BAUSCH & LOMB INCORPORATED (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-2026818-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | Bodor, Nicholas S. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1658083-B1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SELECTED ANTI-INFLAMMATORY STEROIDS | BODOR NICHOLAS S (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1653974-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR, Nicholas S. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005000317-A1 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION | BODOR NICHOLAS S (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6541463-B1 | 17-spirolactone derivatives of steroids | ENDORECHERCHE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | disclosed |
| US-5268477-A | Containing a pyrrolidine or pyridine ring structure | THE UPJOHN COMPANY (US) | 1993-12-07 | — | — | US | disclosed |
| US-5175281-A | Antiulcer, antiinflammatory, antiischemic, antiallergen, antisecretory, wound healing agents; cardiovascular disorders | THE UPJOHN COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
| US-5099019-A | Central nervous system steroid derivative drugs | UPJOHN COMPANY (US) | 1992-03-24 | — | — | US | disclosed |
| WO-1990005528-A2 | ANTI-THROMBOTIC STEROIDS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1990-05-31 | — | — | WO | disclosed |
| EP-0263213-A1 | C20 Through C26 amino steroids | THE UPJOHN COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | disclosed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | disclosed |
| US-4348327-A | Process for the preparation of 17α-hydroxy- and 17aα-hydroxy-D-homoetiocarboxylic acids | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| US-4252729-A | Steroids and process for their manufacture | HOFFMANN-LA ROCHE INC. (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | LMNA 3211/4885SHBG 33/4885SMN1; SMN2 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.